Antiviral Therapy for Children: Topical Issues and Modern Approaches
On March 14, 2018, the 10th Scientific and Practical Conference on Contemporary Issues in Pediatrics was held with the participation of Valenta Pharm in Moscow. The conference focused on topical issues of therapy of viral, bacterial and infectious diseases in children.
The discussion of such pressing issue as application of various therapeutic agents in treatment of influenza and ARVI was a separate section of the conference. According to the Federal Service on Customers’ Rights Protection and Human Well-being Surveillance (Rospotrebnadzor)1, the relative number of patients with influenza to the total number of patients with ARVI in Moscow in early March 2018 amounted to only 0.11%.
In recent years, scientists around the world, including Russia, have been actively working on development of innovative antiviral agents facilitating accelerated viruses elimination, reduction of disease duration and complications minimization. A.N. Goryainova, Candidate of Medical Science, Associate Professor of Pediatrics Department named after G.N. Speransky, Russian Medical Academy of Continuous Professional Education (RMACPE) of the Ministry of Health of the Russian Federation cited in her report the data on a multicenter clinical study of Ingavirin® involving 310 children at the age of 7-122. On the third day after the treatment initiation, 82.6% of patients taking Ingavirin® showed normalization of their body temperature , whereas in the placebo group only 62.6% showed such body temperature normalization; the duration of fever in general for the group taking Ingavirin® was 42 hours, and 54.5 hours in the placebo group3. The difference in the duration of intoxication and catarrhal syndromes in both groups was also significant. Due to the stimulation of the innate immunity factor, the action mode of Ingavirin® is implemented at the level of infected cells; the maximum effect can be achieved if treatment is initiated in the first 48 hours of the disease. The attention was also drawn to a high safety profile of the medicines, including the safety of its administration in the studied age group2,3.
The issues, discussed at the conference, aroused a keen interest among the medical practitioners. Over 600 pediatricians and general practitioners from all over Russia participated in the event. They were able to ask questions to the leading specialists of the Pediatrics Department of RMACPE, and took part in interactive discussions and analysis of challenging clinical cases.
- 1 Information on the epidemiological situation on influenza and ARVI in Moscow for the 10th week of 2018.URL: http://77.rospotrebnadzor.ru/index.php/san-epid/40-2009-08-20-06-08-14/6000-ob-epidemiologicheskoj-situatsii-po-grippu-i-ostrym-respiratornym-virusnym-infektsiyam-v-gorode-moskve-za-10-nedelyu-2018-goda-s-5-po-11-marta
- 2 I.M. Farber, N.A. Geppe, D.V. Reikhart, V.E. Nebolsin, V.S. Arnautov, A.A. Globenko. Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes. Rossiysky Vestnik Perinatologii i Pediatrii, 2, 2016. http://www.ingavirin.ru/userfiles/file/50-2015_Farber_Gripp_i_ORVI_deti_7-12_ING_60.pdf
- 3 Patient information leaflet for Ingavirin® LP-002968.